STAT3 SIGNALING: Anticancer Strategies and Challenges

Table 1

STAT3 in the Context of Various Cancers: Validation as an Anticancer Target

Cancers Characterized by Elevated STAT3 Expression or Activity Poor Prognosis Linked to High STAT3 Levels Upstream/Downstream Abnormalities of STAT3 Signaling Xenograft Models Responsive to Inhibition of STAT3
Multiple myeloma
Breast cancer
Prostate carcinoma
Lung cancer (non-small-cell)
Renal cell carcinoma lung cancer
Hepatocellular carcinoma
Ovarian carcinoma
Pancreatic adenocarcinoma
Head and neck squamous cell carcinoma
Renal cell carcinoma
Colorectal cancer
Ovarian carcinoma
Gastric carcinoma
Intestinal-type gastric adenocarcinoma
Cervical squamous-cell carcinoma
Epithelial ovarian carcinoma
Elevated EGFR expression
Constitutively activated EGFR-RTK
Overexpression of SFKs
Hyperactivated JAKs
Elevated TGFα/IL-6
Head and neck squamous cell carcinoma
Myeloproliferative neoplasms
Renal cell carcinoma
Breast cancer
Lung adenocarcinoma
Acute lymphoblastic leukemia

This Article

  1. MI February 2011 vol. 11 no. 1 18-26